Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Niraparib, Dostarlimab, and Radiotherapy in Locally-advanced Rectal Cancers
NCT04926324Phase 1Terminated
- Sponsor
- University of Iowa
- Start
- Jul 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of niraparib in rectal cancer (2 cohorts), sponsored by University of Iowa. Primary endpoints: Recommended Phase 2 Niraparib Dose at 16 weeks and Clinical Complete Response Rate. Started Jul 2022; status: terminated.
02
Drugs
niraparib
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04926324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04926324.